HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Hillhouse Capital Related

469.111

-4.840-1.02%

Number of Gainers:18

Number of Losers:29

Number of Flat:4

PE:- -

High:475.542

Open:474.006

Low:466.941

Close:473.951

Volume:397.13M

Turnover:11.96B

Market Cap:2.95T

Float Cap:2.06T

Loading ...

SUNAC Shares Surge Over 9% in Morning Trade Following Strategic Shift to Asset Management and Operations

Hong Kong Stocks in Focus: CRO Sector Rallies as Offshore CXO Leaders Post Strong Results

Hong Kong Stock Market Update | JXR Surges Over 4% in Morning Trade on Strong H1 Results and Strategic Focus on VIP and International Expansion

The Bell Rings, $170 Billion Vanishes: Why Isn't Wang Xingxing Smiling?

Is Xtep International Holdings (SEHK:1368) Undervalued After Its Shanghai Running Tech Launch?

Simply Wall St.

Interim Results Analysis: PEIJIA-B's Core AR Product Exceeds Expectations, Reinforcing Profitability Signals and Investment Certainty

RemeGen Swings to Profit in H1 as Revenue Surges Fivefold

MT Newswires Live

Antengene Receives Clinical Trial Approval in Australia for Phase I Attract Study of Atg-201 (Cd19 X Cd3 Tce) in B Cell-Related Autoimmune Diseases

THOMSON REUTERS

Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy

Antengene Says Australia HREC Clears Phase 1 Attract Trial of ATG-201 in B-Cell Autoimmune Diseases

Antengene Corp - Receives Hrec Approval for Phase I Attract Study of Atg-201 in Australia

THOMSON REUTERS

Wuxi AppTec Resolves DEL Platform Security Breach, Continues Investigation With Cyber Specialists

mRNA Sector Marks Historic Clinical Win, Everest Medicines' Self-Developed Pipeline Gains Prominence

China's Shanghai INT Medical Instruments H1 Revenue Jumps on Acquisitions

China's Peijia Medical H1 Revenue Jumps on Transcatheter Valve Therapeutics Growth

Peijia Medical H1 Revenue RMB 424.5 Million

THOMSON REUTERS

Press Release: Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth

JXR Buys Back 1.346 Million Shares on August 24 for HK$2.999 Million

China's InnoCare Pharma H1 Revenue Surges, Partly on Orelabrutinib Growth

Conch Cement Completes Share Buyback Worth RMB17.06 Million on August 24

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/BK1583/news?page=19"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":469.11102,"timestamp":1788250091886,"preClose":473.95062,"halted":0,"volume":397125506,"delay":0,"changeRate":-0.010211,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-4.8396,"latestTime":"09-01 16:00:00","open":474.00632,"high":475.5418,"low":466.94058,"amount":11957903003,"amplitude":0.018148,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788312600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788226200000,1788235200000],[1788238800000,1788249600000]],"pbRate":2.140289,"peRate":44.408694,"turnoverRate":0.003652,"increases":16,"decrements":29,"flats":4,"marketCap":2949796327648,"floatMarketCap":2064055102368},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":475.5418,"amplitude":0.018148,"preClose":473.95062,"low":466.94058,"pbRate":"2.140289","latestPrice":469.11102,"volume":397125506,"delay":0,"open":474.00632,"prevYearClose":503.90085,"prevWeekClose":483.681,"prevMonthClose":473.951,"prevQuarterClose":402.118,"fiveDayClose":475.733,"twentyDayClose":471.019,"sixtyDayClose":425.31,"secType":"PLATE","market":"HK","turnoverRate":0.003652,"peRate":44.408694,"marketCap":2949796327648,"floatMarketCap":2064055102368,"timestamp":1788250091886,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":18,"down":29,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:19,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1161068692","title":"SUNAC Shares Surge Over 9% in Morning Trade Following Strategic Shift to Asset Management and Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=1161068692","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161068692?lang=en_us&edition=fundamental","pubTime":"2026-08-25 11:44","pubTimestamp":1787629454,"startTime":"0","endTime":"0","summary":"SUNAC (01918) saw its share price climb more than 9% in early trading, last up 7.34% at HK$0.585 with turnover reaching HK$110 million. The move comes after the company announced a major strategic...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VXUS","AMGR","BK1258","PFI","01918","BK1229","BK1583","ADVX","BK1555","09983","BK4588","KCAI","BK1542","BK1240","TRUF","BK1521","GABF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190498853","title":"Hong Kong Stocks in Focus: CRO Sector Rallies as Offshore CXO Leaders Post Strong Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1190498853","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190498853?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:24","pubTimestamp":1787624657,"startTime":"0","endTime":"0","summary":"Shares of contract research organization (CRO) companies are leading gains in Hong Kong trading, driven by a wave of better-than-expected earnings from global CXO industry leaders that underscores a...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","HK0000306685.HKD","HK0000306701.USD","LU0359201612.USD","LU0029874061.USD","BK1191","BK1576","LU0823426480.USD","LU1880383366.USD","LU0516422366.SGD","06821","BK1583","BK4588","BK1589","LU0327786744.USD","LU1242518857.USD","WX","BK1610","LU0052750758.USD","LU1794554557.SGD","SG9999002562.SGD","LU0348825331.USD","LU2039709279.SGD","LU0359202008.SGD","LU3063872942.SGD","LU0516422952.EUR","LU0823426308.USD","LU0417516902.SGD","KURE","LU0708995583.HKD","BK1141","HK0000320264.USD","LU0819121731.USD","LU0326950275.SGD","LU0456827905.SGD","LU0320764599.SGD","CXO","01548","LU0856984785.SGD","LU0417516738.SGD","SG9999002463.SGD","LU1720050803.USD","LU0051755006.USD","LU0128526141.USD","LU0516422440.USD","LU0039217434.USD","LU0140636845.USD","LU0516423091.SGD","KCAI","LU0043850808.USD","LU0588546209.SGD","BK1521","LU1242518931.SGD","VXUS","BK4585","LU0572944931.SGD","LU1688375341.USD","HK0000320223.HKD","LU0979878070.USD","LU0456846285.SGD","LU0181495838.USD","03347","LU0307460666.USD","02269","IE00B0JY6N72.USD","LU0516423174.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141600911","title":"Hong Kong Stock Market Update | JXR Surges Over 4% in Morning Trade on Strong H1 Results and Strategic Focus on VIP and International Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1141600911","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141600911?lang=en_us&edition=fundamental","pubTime":"2026-08-25 09:56","pubTimestamp":1787622988,"startTime":"0","endTime":"0","summary":"JXR (01951) climbed more than 4% during Tuesday's morning session before settling with a 2.01% gain at HK$2.275, recording turnover of HK$17.83 million. The stock's upward momentum follows the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1219","BK1583","BK4023","VIP","01951","KCAI","BK4585","VXUS","BK1597"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155854965","title":"The Bell Rings, $170 Billion Vanishes: Why Isn't Wang Xingxing Smiling?","url":"https://stock-news.laohu8.com/highlight/detail?id=1155854965","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155854965?lang=en_us&edition=fundamental","pubTime":"2026-08-25 09:31","pubTimestamp":1787621507,"startTime":"0","endTime":"0","summary":"On August 19, Unitree Robotics made its stock market debut. The opening price of 1,100 yuan represented a 629% surge from the IPO price of 150.8 yuan, briefly pushing the company's market...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0871576103.HKD","LU0049853897.USD","IE00B29SXG58.USD","LU0348825331.USD","BK4122","HMTD.SI","BK1604","LU1152091168.USD","LU1868837565.USD","LU1868837722.USD","IE00BPRC5H50.USD","LU0828237510.HKD","BK1142","LU1152091754.HKD","LU0326948709.USD","LU0501845795.SGD","LU0072913022.USD","LU0314109678.HKD","IE00B543WZ88.USD","LU2148510915.USD","LU0132412106.USD","LU1481107354.HKD","LU0269904917.USD","BK1610","IE00B3M56506.USD","LU0214875030.USD","LU0502904849.HKD","LU0823039010.USD","LU0868486357.SGD","LU0456846285.SGD","LU0611395673.USD","LU2257852520.SGD","LU0541502299.USD","LU0455707207.USD","IE0032431581.USD","LU2399975544.HKD","LU1242518857.USD","LU1734074674.USD","LU0499858438.USD","LU0594300419.USD","LU0979878070.USD","LU0672654166.SGD","LU0320764755.SGD","LU0633140727.USD","SG9999002562.SGD","LU0577902298.EUR","LU1813983027.USD","LU0181495838.USD","LU0456827905.SGD","SG9999001689.USD","LU0143863784.USD","LU0650527681.SGD","LU0029875118.USD","LU1105468828.SGD","LU0797268264.HKD","LU0047713382.USD","LU1188198961.HKD","LU0054237671.USD","LU0370786039.SGD","LU0345775950.USD","LU2097828631.EUR","LU0287142896.SGD","SG9999001903.USD","LU0819123356.HKD","LU0345776255.USD","LU1960683339.HKD","LU1993786604.SGD","LU0165289439.USD","DRAG","LU0449515922.USD","LU0683595622.HKD","LU0605514214.HKD","LU1719994722.HKD","LU0594300179.USD","LU1251922891.USD","LU0540923850.HKD","BK4209","LU0039217434.USD","LU0463099449.HKD","LU0823041008.USD","LU0244354667.USD","LU0173614495.USD","LU0873338254.USD","LU0359202008.SGD","KWEB","LU0431992006.USD","BK1615","BK1233","LU0348788117.USD","LU1868838027.USD","LU0210526637.USD","LU0708995583.HKD","BK1591","LU1770034418.SGD","LU0572944931.SGD","LU2476274720.SGD","SG9999000327.SGD","MPNGY","LU0633140560.USD","LU0348816934.USD","LU0819121731.USD","LU0320764599.SGD","LU0577902454.USD","LU0856984785.SGD","LU0315178854.USD","LU1808992512.USD","LU1720050803.USD","BK1575","LU1226287529.USD","LU1323998911.USD","BK1583","LU0588545490.SGD","LU1961090484.USD","LU1880383366.USD","LU0878005551.USD","LU2097828557.USD","LU0084288322.USD","IE0008369823.USD","LU1770036033.HKD","LU0048580855.USD","LU0828238088.HKD","LU1328277881.USD","LU0577902371.SGD","LU1794554557.SGD","LU0577902538.SGD","LU0164872284.USD","LU0348805143.USD","LU0509642566.USD","LU0577902611.USD","BK1589","LU0593848301.USD","LU1303224171.USD","LU1688375341.USD","LU1880383440.USD","LU0823038988.USD","SG9999002463.SGD","LU0348827113.USD","LU0499858602.USD","LU1023057109.AUD","LU0531971595.HKD","LU1224709979.USD","LU1675838814.USD","LU1102505929.USD","LU1242518931.SGD","LU2152927971.USD","LU0143863198.USD","LU0149721374.USD","LU0543330483.HKD","LU0828237940.HKD","LU0051755006.USD","LU2097828714.EUR","BK1618","LU0541501648.USD","LU0449509016.USD","LU2242644610.SGD","IE00B031HY20.USD","LU0359201885.HKD","LU0588546209.SGD","LU0823426480.USD","LU0196878994.USD","LU1008478684.HKD","LU0588545904.SGD","LU0417516738.SGD","LU0634319403.HKD","SG9999002828.SGD","LU0228659784.USD","SG9999014674.SGD","BK1521","LU0307460666.USD","LU0589944569.HKD","LU0211977185.USD","LU0561508036.HKD","LU1328615791.USD","LU0348814723.USD","IE00B5MMRT66.SGD","LU0588545730.USD","LU0251144936.SGD","LU0417516902.SGD","LU1282648689.USD","LU2226246903.HKD","LU2778985437.USD","LU0918141887.USD","LU0140636845.USD","LU0048597586.USD","LU2087589342.USD","IE00B0JY6N72.USD","LU2476274308.USD","METmain","LU0164865239.USD","LU0918141705.HKD","LU2488822045.USD","LU0823040885.USD","LU0359201612.USD","LU1048588211.SGD","IE0008368742.USD","IE00BF5LJ272.USD","LU1064131003.USD","LU0880133367.SGD","LU0054450605.USD","LU1807302812.USD","LU0043850808.USD","LU0072462343.USD","LU0106252389.USD","LU0128522157.USD","LU0326950275.SGD","LU0821914370.USD","LU1102505762.USD","LU2045819591.USD","SG9999000459.SGD","LU2097828805.USD","LU2125910500.SGD","LU0327786744.USD","LU1064130708.USD","LU2039709279.SGD","LU1831875114.USD","LU0348735423.USD","LU2097828474.EUR","LU0261950983.USD","LU0052750758.USD","IE0034224299.USD","LU0700851271.USD","LU0067412154.USD","LU0231483743.USD","LU0164880469.USD","LU0823426308.USD","LU0737861699.HKD","LU0117841782.USD","LU0011963245.USD","LU1048596156.SGD","LU0865486749.SGD","03690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662785780","title":"Is Xtep International Holdings (SEHK:1368) Undervalued After Its Shanghai Running Tech Launch?","url":"https://stock-news.laohu8.com/highlight/detail?id=2662785780","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662785780?lang=en_us&edition=fundamental","pubTime":"2026-08-25 09:22","pubTimestamp":1787620944,"startTime":"0","endTime":"0","summary":"Xtep International Holdings (SEHK:1368) has drawn fresh attention after hosting a 2026 Full Scenario Running New Product Launch Conference in Shanghai, where it unveiled dual flagship technologies aimed at both elite racers and everyday runners.\nSee our latest analysis for Xtep International Holdings.\nFor investors, the latest running shoe launches arrive against a weaker share price backdrop, with Xtep International Holdings closing at HK$3.57 and recording a 90-day share price return that...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/4131000-choice1-main-header/1585186707756","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4131000-choice1-main-header/1585186707756"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/consumer-durables/hkg-1368/xtep-international-holdings-shares/news/is-xtep-international-holdings-sehk1368-undervalued-after-it","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/consumer-durables/hkg-1368/xtep-international-holdings-shares/news/is-xtep-international-holdings-sehk1368-undervalued-after-it","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01368","BK1168","BK1583","LU0702159699.USD","LU1166156734.SGD","BK1502","LU0702159343.USD","BK1512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114204276","title":"Interim Results Analysis: PEIJIA-B's Core AR Product Exceeds Expectations, Reinforcing Profitability Signals and Investment Certainty","url":"https://stock-news.laohu8.com/highlight/detail?id=1114204276","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114204276?lang=en_us&edition=fundamental","pubTime":"2026-08-25 09:02","pubTimestamp":1787619757,"startTime":"0","endTime":"0","summary":"During the first half of this year, Hong Kong-listed pharmaceutical and medical device stocks underwent a phase of valuation digestion alongside an industrial logic reshuffle, marked by notable...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","AR","BK4213","159891","09996","METV","LNGX","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662026272","title":"RemeGen Swings to Profit in H1 as Revenue Surges Fivefold","url":"https://stock-news.laohu8.com/highlight/detail?id=2662026272","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662026272?lang=en_us&edition=fundamental","pubTime":"2026-08-25 08:36","pubTimestamp":1787618181,"startTime":"0","endTime":"0","summary":"RemeGen  posted an attributable profit of 4.66 billion yuan in the first half of 2026, rebounding from an attributable loss of 449.57 billion yuan a year ago.Earnings per share came in at 8.32 yuan, compared with a loss per share of 0.83 yuan a year earlier, according to a Monday filing with the Hong Kong Exchange.Revenue surged year over year to 5.85 billion yuan from 1.09 billion, the biopharmaceutical company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688331","FCA","LU2148510915.USD","BK1574","09995","BK0239","LU1064131003.USD","LU1969619763.USD","BK1161","LU2328871848.SGD","BK1583","LU2488822045.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662025552","title":"Antengene Receives Clinical Trial Approval in Australia for Phase I Attract Study of Atg-201 (Cd19 X Cd3 Tce) in B Cell-Related Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2662025552","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662025552?lang=en_us&edition=fundamental","pubTime":"2026-08-25 08:30","pubTimestamp":1787617800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUABJPBPM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1583","BK1191","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179996720","title":"Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1179996720","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179996720?lang=en_us&edition=fundamental","pubTime":"2026-08-25 07:04","pubTimestamp":1787612662,"startTime":"0","endTime":"0","summary":"Antengene-B (06996) has announced a significant regulatory milestone, with its self-developed investigational drug ATG-201 receiving approval from the Australian Human Research Ethics Committee...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996","BK1574","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201482","title":"Antengene Says Australia HREC Clears Phase 1 Attract Trial of ATG-201 in B-Cell Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201482","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201482?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:42","pubTimestamp":1787611365,"startTime":"0","endTime":"0","summary":"Antengene says Australia HREC clears Phase 1 ATTRACT trial of ATG-201 in B-cell autoimmune diseasesAntengene secured Australian HREC clearance for its Phase 1 ATTRACT trial of ATG-201 in B-cell-mediat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL84Czw1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1191","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201488","title":"Antengene Corp - Receives Hrec Approval for Phase I Attract Study of Atg-201 in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201488?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:42","pubTimestamp":1787611362,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L0US:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","06996","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156947639","title":"Wuxi AppTec Resolves DEL Platform Security Breach, Continues Investigation With Cyber Specialists","url":"https://stock-news.laohu8.com/highlight/detail?id=1156947639","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156947639?lang=en_us&edition=fundamental","pubTime":"2026-08-24 23:00","pubTimestamp":1787583626,"startTime":"0","endTime":"0","summary":"Wuxi AppTec has announced that the security issue affecting its DNA Encoded Library (DEL) platform has been brought under control, following a recent cybersecurity incident that resulted in...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603259","LU2488822045.USD","BK1583","LU0572944931.SGD","LU1808992512.USD","LU0052750758.USD","LU1046422090.SGD","LU1997244956.HKD","LU1934453819.USD","LU0708995583.HKD","LU2495084118.USD","LU1770034418.SGD","LU0320764599.SGD","LU1997245177.USD","LU2125910500.SGD","LU0456842615.SGD","IE00B543WZ88.USD","LU2328871848.SGD","BK1576","LU1969619763.USD","IE00BPRC5H50.USD","LU0700851271.USD","LU0469268626.HKD","BK0216","LU1719994722.HKD","LU1303224171.USD","LU0611395673.USD","LU1979443071.USD","BK1141","02359","IE00B5MMRT66.SGD","LU0348766576.USD","LU1997245094.SGD","LU2242644610.SGD","LU0348767384.USD","LU0327786744.USD","LU1251922891.USD","LU2045819591.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167515089","title":"mRNA Sector Marks Historic Clinical Win, Everest Medicines' Self-Developed Pipeline Gains Prominence","url":"https://stock-news.laohu8.com/highlight/detail?id=1167515089","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167515089?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:52","pubTimestamp":1787583127,"startTime":"0","endTime":"0","summary":"On August 19, Moderna and Merck jointly unveiled positive topline results from the global Phase III INTerpath-001 study evaluating the individualized neoantigen mRNA therapy intismeran autogene...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1161","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271618","title":"China's Shanghai INT Medical Instruments H1 Revenue Jumps on Acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271618","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271618?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:23","pubTimestamp":1787577791,"startTime":"0","endTime":"0","summary":"China's Shanghai INT Medical Instruments H1 revenue jumps on acquisitionsOverviewChina medical device maker's H1 revenue rose 29% yr/yr, driven by acquisitions and higher device salesProfit for the pe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44L0H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1222","BK0239","01501","688428","BK1100","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661919276","title":"China's Peijia Medical H1 Revenue Jumps on Transcatheter Valve Therapeutics Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2661919276","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661919276?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:14","pubTimestamp":1787573695,"startTime":"0","endTime":"0","summary":"China's Peijia Medical H1 revenue jumps on transcatheter valve therapeutics growthOverviewChina medical device maker's interim revenue grew 20.1% yr/yr, reaching RMB424.5 mlnCompany achieved first-eve","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44L0EE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996","BK1574","BK0239","BK1583","BK1100","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661514276","title":"Peijia Medical H1 Revenue RMB 424.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661514276","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661514276?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:05","pubTimestamp":1787573138,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nPLXSHDW3L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","09996","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661570276","title":"Press Release: Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2661570276","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661570276?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572800,"startTime":"0","endTime":"0","summary":"SUZHOU, China, Aug. 24, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","09996","BK4232","R","BK4022","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184137817","title":"JXR Buys Back 1.346 Million Shares on August 24 for HK$2.999 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1184137817","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184137817?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:26","pubTimestamp":1787570776,"startTime":"0","endTime":"0","summary":"JXR announced that on August 24, 2026, the company repurchased 1.346 million shares at a total cost of HK$2.999 million.This buyback reflects the company's ongoing capital management strategy,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1597","BK1583","01951","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661227355","title":"China's InnoCare Pharma H1 Revenue Surges, Partly on Orelabrutinib Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2661227355","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661227355?lang=en_us&edition=fundamental","pubTime":"2026-08-24 17:44","pubTimestamp":1787564642,"startTime":"0","endTime":"0","summary":"China's InnoCare Pharma H1 revenue surges, partly on orelabrutinib growthOverviewChina biopharmaceutical firm's H1 revenue grew 55.5% yr/yr, driven by drug sales and collaborationsAdjusted net income ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44L0AM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","HK0000306685.HKD","BK1230","BK1161","688428","ZBIO","BK1191","HK0000320264.USD","BK1583","00656","06996","BK4139","BK0239","HK0000306701.USD","HK0000320223.HKD","02696","HK0000165453.HKD","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145511160","title":"Conch Cement Completes Share Buyback Worth RMB17.06 Million on August 24","url":"https://stock-news.laohu8.com/highlight/detail?id=1145511160","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145511160?lang=en_us&edition=fundamental","pubTime":"2026-08-24 16:42","pubTimestamp":1787560946,"startTime":"0","endTime":"0","summary":"Conch Cement (00914) has announced that on August 24, 2026, the company spent approximately RMB17.06 million to repurchase 970,000 A-shares.The buyback price ranged from RMB17.53 to RMB17.66 per share, as detailed in the company's official filing.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["399300","02846","07233","BK0183","BK1505","BK1147","02827","BK0235","BK1135","BK0015","600585","03188","BK1507","BK0028","BK0196","83130","BK0188","BK0044","BK1583","82846","BK1594","LU1328615791.USD","BK0187","00914","BK1563","159982","BK0012","83188","03130"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":28,"pageCount":19,"totalSize":542,"code":"91000000","status":"200"}]}}